Enanta Pharmaceuticals Inc

Ownership Transactions Reported by 17 Insiders

Symbol
ENTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
4 Kingsbury Avenue, Watertown, MA

Insiders trading volume in the past year

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Jay R. Luly President and CEO, Director $4.83M +$215K +4.65% Feb 12, 2025
Yat Sun Or Chief Scientific Officer $2.09M -$20.9K -0.99% Feb 12, 2025
Nathaniel S. Gardiner Chief Legal Officer $1M Feb 26, 2024
Paul J. Mellett Chief Fin. & Admin Officer $536K -$20.9K -3.75% Feb 12, 2025
Nathalie Adda Sr. VP & Chief Medical Officer $319K Apr 1, 2022
Brendan Luu Chief Business Officer $225K -$18.4K -7.57% Feb 12, 2025
Tara Lynn Kieffer Chief Product Strategy Officer $187K -$18.4K -8.95% Feb 12, 2025
Scott T. Rottinghaus Chief Medical Officer $158K -$6.98K -4.23% Aug 8, 2025
Harry R. Trout III Vice President, Finance $80.1K Aug 26, 2025
Kathleen S. Capps Executive Director, Accounting & Controller; Exhibit 24 Power of Attorney filed herewith. $42.8K Aug 26, 2025
Mark G. Foletta Director Mar 13, 2025
Kristine Peterson Director Mar 13, 2025
Lesley Russell Director Mar 13, 2025
Yujiro S. Hata Director Mar 13, 2025
Matthew Paul Kowalsky Chief Legal Officer Nov 27, 2024
Terry Vance Director Mar 13, 2025
L. Carter Bruce Director Mar 13, 2025

Recent Insider Transactions by Companies or Individuals for Enanta Pharmaceuticals Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.